Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2026

Segment Reporting

Schedule of reconciliation of the company's net income (loss)

The table below shows a reconciliation of the Company’s net (loss) income, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under GAAP, to the Company’s net (loss) income in the condensed consolidated statements of operations and comprehensive (loss) income (in thousands):

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Direct research and development expenses by program:
TTI-101:
HCC	$	1,118	$	967	$	1,818	$	1,404
IPF		137		2,830		137		3,863
mBC		(5)		(268)		(5)		(268)
Pre-clinical, CMC, and other (unallocated) (1)		105		140		192		315
TTI-109		1,362		822		4,264		1,180
Unallocated research and development expense:
Personnel costs		926		917		1,930		1,775
Consultant fees and other costs (2)		359		398		577		648
General and administrative expense:
Personnel costs		933		1,038		1,865		1,647
Other general and administrative expenses (3)		1,694		2,025		2,902		2,659
Interest income		(172)		(377)		(419)		(652)
Other income, net		—		(12,659)		—		(7,159)
Net (loss) income	$	(6,457)	$	4,167	$	(13,261)	$	(5,412)

⁽¹⁾ Pre-clinical, chemistry, manufacturing and control (CMC), and other (unallocated) costs include preclinical testing, CMC, and other direct research and development expenses that are not allocated to a specific program.

⁽²⁾ Consultant fees and other costs include expenses incurred for research and development consultants as well as payroll costs for employees within the research and development function.

⁽³⁾ Other general and administrative expenses include professional fees, accounting services, rent, and other overhead and administrative expenses.